KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally

[
KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally
[og_img]
https://www.investing.com/news/press-releases/keytruda–pembrolizumab-as-perioperative-treatment-with-standard-of-care-soc-adjuvant-therapy-significantly-improved-eventfree-survival-compared-to-soc-alone-in-patients-with-resectable-locally-93CH-4006003


Investing.com